Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke

A legfontosabb adatok

Ki végzi
Affiliated Hospital of Nantong University
Hol
Nantong (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
200 fő, tervezett
Kezdés
2025. nov. 19.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2025. december 9.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek most volt az első ischaemiás stroke-juk, valamint egészséges felnőtteket összehasonlító csoportnak. A bélbaktériumokat és a gyulladást vizsgálják.

Életkor
18 év vagy idősebb
Nem
Bármely nemű személy részt vehet.
A betegség stádiuma
Első alkalommal kialakult akut ischaemiás stroke, legalább 4 pontos stroke-súlyossági értékkel (NIHSS). A mintákat a tünetek kezdetétől és a kórházi felvételtől számított 48 órán belül kell levenni.
Korábbi kezelés
A stroke-os betegek a kórházi felvétel előtti egy hónapban és a követés alatt nem szedhettek antibiotikumot vagy probiotikumot.

A részvétel fő kizáró okai

  • Fertőzés, például tüdőgyulladás vagy húgyúti fertőzés
  • Nem tud székletmintát adni a felvételt követő három napon belül vagy a három hónapos követés alatt
  • Súlyos szív-, tüdő-, máj- vagy vesebetegség
  • Korábbi súlyos bélbetegség
  • Más súlyos idegrendszeri betegség

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • (1) First-time acute ischemic stroke patients must have completed initial sample collection within 48 hours of symptom onset and hospital admission; (2) Participants must be aged 18 or older, with no gender restrictions; (3) Stroke patients must have a National Institutes of Health Stroke Scale (NIHSS) score of 4 or higher; (4) Participants must fully understand the study protocol and provide informed consent

Ki nem vehet részt

  • (1) Patients who have taken antibiotics or probiotics within one month prior to hospitalization or during follow-up; (2) Patients with infectious diseases such as pneumonia or urinary tract infections; (3) Patients who cannot obtain stool samples within three days after hospitalization or during three-month follow-up; (4) Patients with severe dysfunction of major organs including heart, lungs, liver, or kidneys; (5) Patients who have not provided or are unable to provide informed consent; (6) Patients with a history of major gastrointestinal diseases; (7) Patients with other severe neurological disorders; (8) Patients deemed unsuitable by investigators to participate in this clinical study

Helyszínek itt: Kína

  • Affiliated Hospital of Affiliated HospitalNantong, KínaContact: Gao YT Director of the Department of Anesthesiology, MasterRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

1. Stroke stands as one of the leading causes of death and long-term disability worldwide, imposing a substantial socioeconomic burden. Annual new stroke cases are estimated between 9.5 million and 10.6 million. Stroke survivors commonly face challenges of poor long-term functional outcomes and compromised immunity, which not only drive quality-of-life deterioration but also fuel the persistent escalation of socioeconomic burdens. However, current clinical treatments for stroke prognosis improvement remain limited. In recent years, with the emergence of the "microbiota-gut-brain axis" concept and advancing research, the role of gut microbiota in stroke onset, progression, and prognosis regulation has garnered increasing attention.

A teljes eredeti leírásKevesebb

The gut-brain axis is a complex bidirectional communication network connecting the central nervous system with the gut and its microbiota, centered on the integration of the microbiota-gut-brain axis concept. Its signaling mechanisms primarily involve multiple pathways including neural (e.g., vagus nerve), endocrine (e.g., HPA axis and gut hormones), immune (e.g., cytokines), and microbial metabolic pathways (e.g., short-chain fatty acids (SCFAs) and neuroactive substances). Dysregulation of the gut-brain axis has been proven closely associated with various diseases, including irritable bowel syndrome (IBS) characterized by visceral hypersensitivity and motility abnormalities, inflammatory bowel disease (IBD) often accompanied by emotional comorbidities, autism spectrum disorder (ASD) with gastrointestinal symptoms and behavioral core symptoms, depression and anxiety related to microbiota dysbiosis and inflammation, as well as Parkinson's disease (PD) with pathological origins potentially originating in the gut. Recent studies support that gut microbiota interact with ischemic stroke through the gut-brain axis, thereby modulating stroke pathogenesis. Gut microbiota can regulate innate and adaptive immune responses and their derived metabolites through neural pathways, influencing host brain function and behavior. Gut microbiota metabolites-short-chain fatty acids (SCFAs) such as butyrate-reduce neuroinflammation and brain injury by promoting regulatory T cell differentiation and secretion of anti-inflammatory factors IL-10 and TGF-β, suppressing pro-inflammatory Th1/Th17 responses, and enhancing expression of blood-brain barrier tight junction proteins Occludin and ZO-1.

Compared to traditional stroke treatments, gut microbiota therapy breaks the time window limitation. Even days after stroke, restoring a youthful gut microbiome can reduce neuroinflammation and promote recovery in stroke patients. This effect is largely mediated by metabolites produced by bacteria, particularly short-chain fatty acids.

Although existing studies have demonstrated the crucial role of gut microbiota in stroke treatment, the mechanisms underlying its effects on improving physiological and behavioral functions in stroke patients, as well as the underlying mechanisms, remain insufficiently explored. 2. Purpose of this study To investigate the mechanisms by which gut microbiota and their metabolites improve the physiological and neurological functions of stroke patients, and to provide new therapeutic approaches for improving the prognosis of stroke patients. 3. Research Design 3.1 Research Methodology This is a single-center, non-interventional, cohort-controlled clinical study that randomly enrolled 100 stroke patients and 100 healthy individuals. The participants were divided into a stroke group (case group, CS group) and a healthy control group (CON group), with 100 cases in each group. The primary objectives were to investigate the gut microbiota composition, intestinal barrier function, and inflammatory cytokine levels in stroke patients versus healthy controls, while exploring the mechanisms of beneficial gut microbiota in stroke recovery. This research may provide new therapeutic approaches to address current treatment limitations.

A vizsgálat 2 csoportja

  • Stroke group

    1. For patients with acute ischemic stroke for the first time, the time from symptom onset to hospitalization and completion of the first sample collection was within 48 hours; 2. Over 18 years old, male or female; 3. Patients with ischemic stroke who scored ≥4 on the National Institutes of Health Stroke Scale (NIHSS);

  • Healthy Volunteer Group

    Healthy volunteers with no history of ischemic stroke

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Investigation Into the Gut Microbiota-Immune-Inflammatory Interaction Network and Its Mechanisms in Patients With Ischemic Stroke
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2025. december 9.